CN Patent

CN115177585A — 一种尼莫地平口服溶液及其制备方法

Assigned to Beijing Puli Biopharmaceutical Co ltd · Expires 2022-10-14 · 4y expired

What this patent protects

本发明公开了一种尼莫地平口服溶液及其制备方法，由药物活性成分尼莫地平与甜味剂甘草酸二钠、防腐剂羟苯甲酯以及其他药学上可接受的辅料组成。本发明所提供的口服溶液具有良好的口感和气味，综合接受度高，儿童和老年患者的服药顺应性良好；本发明所提供的口服液的制备方法操作简单，工业操作可行性大，三废排放较少，绿色环保可持续，利于大规模工业化生产，更适合工业化。

USPTO Abstract

本发明公开了一种尼莫地平口服溶液及其制备方法，由药物活性成分尼莫地平与甜味剂甘草酸二钠、防腐剂羟苯甲酯以及其他药学上可接受的辅料组成。本发明所提供的口服溶液具有良好的口感和气味，综合接受度高，儿童和老年患者的服药顺应性良好；本发明所提供的口服液的制备方法操作简单，工业操作可行性大，三废排放较少，绿色环保可持续，利于大规模工业化生产，更适合工业化。

Drugs covered by this patent

Patent Metadata

Patent number
CN115177585A
Jurisdiction
CN
Classification
—
Expires
2022-10-14
Drug substance claim
No
Drug product claim
No
Assignee
Beijing Puli Biopharmaceutical Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.